Management of Patients with Cystic Fibrosis: Defining the Role of Inhaled Tobramycin
Abstract
Cystic fibrosis (CF) is a serious genetically inherited multisystem disease, characterised by symptoms of pancreatic insufficiency, meconium ileus, obstruction/absence of the vas deferens and chronic obstruction, infection and inflammation of the lower respiratory tract. Lung disease, specifically chronic infection caused by Pseudomonas aeruginosa, is the principal cause of morbidity and mortality in patients with CF. Patients with CF require a specialised and integrated programme of care. Proper nutrition, airway clearance and antibacterial therapy are the key components of healthcare for these patients. Inhaled antibacterial therapy, which offers the theoretical benefits of high lung concentrations with minimal risk of systemic toxicity, is sometimes used in this patient group. Inhaled tobramycin, colistin (or colistimethate) and beta-lactam agents (with or without an aminoglycoside) have all been tested as suppressive antipseudomonal therapy, although they have yet to be compared in clinical trials. Recently, tobramycin solution for inhalation (TOBI(R)) has been developed in an attempt to improve on the extemporaneous preparations previously used for this purpose. In patients with CF and confirmed P. aeruginosa infection, 3 courses of a 28-day on/28-day off regimen of inhaled tobramycin (TOBI(R)) significantly improved lung function versus placebo. Patients were permitted to receive other antibiotic treatment as needed. Improvement was sustained for up to 23 months in those who continued the regimen. Inhaled tobramycin also was associated with a 26% reduction in the likelihood of hospitalisation and a 36% reduction in the use of intravenous antipseudomonal antibiotics versus placebo. Although the frequency of bacteria intrinsically resistant to tobramycin did not increase during therapy, fungi (Candida albicans and Aspergillus spp.) were isolated significantly more frequently among tobramycin than placebo recipients. Susceptibility to tobramycin declined steadily among P. aeruginosa during treatment, although the clinical significance of this is difficult to determine. Inhaled tobramycin is generally well tolerated; tinnitus and alteration of the voice occurred in 3 and 13% of patients, respectively. No hearing loss or renal toxicity were reported after 23 months of therapy. Bronchospasm was observed in about 1 in 8 patients. Conclusions: The inhaled formulation of tobramycin is distinguished by a large body of clinical data which should enable clinicians to use the agent appropriately in patients with CF and P. aeruginosa infection. Importantly, for each patient, the risks of hoarseness, fungal coinfection and acquisition cost should be weighed against the benefits of sustained improvement in lung function, reduced hospitalisation, reduced need for parenteral antipseudomonal agents, minimal systemic toxicity and a preservative-free formulation.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic Info
Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.
Volume (Year): 6 (1999)
Issue (Month): 2 ()
Pages: 93-108
Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Handle: RePEc:wkh:dmhout:v:6:y:1999:i:2:p:93-108
Contact details of provider:
Web page: http://diseasemanagement.adisonline.com/
For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).
Related research
Keywords: Reviews-on-treatment; Pseudomonal-infections; Tobramycin; Inhalation; Respiratory-tract-infections; Antibacterials; Colistin; Beta-lactams; Aminoglycosides; Cystic-fibrosis; Bacterial-infections;Find related papers by JEL classification:
- C - Mathematical and Quantitative Methods
- D - Microeconomics
- I - Health, Education, and Welfare
- Z - Other Special Topics
- I1 - Health, Education, and Welfare - - Health
- I19 - Health, Education, and Welfare - - Health - - - Other
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:6:y:1999:i:2:p:93-108For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.